Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study

Autor: Ploder Bettina, Jerzy Windyga, Srilatha Tangada, Margit Serban, L. Rusen, Toshko Lissitchkov, Vasily Mamonov, Oleksandra Stasyshyn

Publikováno v: Clinical and Applied Thrombosis/Hemostasis, Vol 26 (2020)
Clinical and Applied Thrombosis/Hemostasis

This phase 3, prospective, open-label, multicenter, continuation study (NCT01286779) investigated the use of a recombinant factor IX (FIX), nonacog gamma (BAX 326, RIXUBIS®) in patients with severe or moderately severe hemophilia B. The study popula

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::882267560528a45ab9fe6dbec437f598
https://doaj.org/article/53acbf307856414a98abc07531c9dfd7

Zobrazit plný text záznamu

Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq®(human-cl rhFVIII) in previously treated patients with severe haemophilia A

Autor: Jerzy Windyga, Johann Bichler, L. Rusen, Sigurd Knaub, Toshko Lissitchkov, Pencho Georgiev, Yesim Dargaud, Claude Negrier, Robert Klamroth, Cristina Solomon

Publikováno v: Haemophilia. 24:619-627

INTRODUCTION For individuals with haemophilia A, prophylaxis with factor VIII (FVIII) is typically directed towards trough activity >1 IU/dL; however, some patients still experience spontaneous bleeding events (sBEs). AIM Aims were to evaluate relati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7f0faaaba2e0bdb5bbd13802739f917d
https://doi.org/10.1111/hae.13493

Zobrazit plný text záznamu

Plný text ve formátu HTML

Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: Two open-label studies

Autor: L. Rusen, Jeremy Rupon, Pablo Rendo, Kaan Kavakli, Joanne Fuiman, Joan M. Korth-Bradley, James Baumann, Christine Alvey, Francois Huard, Lynne Smith

Publikováno v: Haemophilia. 24:604-610

WOS: 000442583600048
PubMed ID: 29582525
IntroductionThe pharmacokinetics (PK), efficacy and safety of moroctocog alfa (AF-CC) have been demonstrated in haemophilia A patients aged 6years. AimThese studies aimed to further describe moroctoc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d481121f47a0eff06ae5cc64c54cf64
https://doi.org/10.1111/hae.13466

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

PK-guided personalized prophylaxis with Nuwiq®(human-cl rhFVIII) in adults with severe haemophilia A

Autor: Pencho Georgiev, Larisa Belyanskaya, Toshko Lissitchkov, Olaf Walter, Sigurd Knaub, Jerzy Windyga, Andreas Tiede, L. Rusen, K. J. Pasi, Liana Gercheva, Johann Bichler, László Nemes, Robert Klamroth

Publikováno v: Haemophilia. 23:697-704

Introduction Nuwiq® (human-cl rhFVIII) is a 4th generation recombinant human FVIII, without chemical modification or protein fusion, produced in a human cell-line. Aims/Methods This study (NuPreviq) was a prospective, open-label, multicentre, phase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::05279f37fd6d8c2674bb2be7063a7a75
https://doi.org/10.1111/hae.13251

Zobrazit plný text záznamu

Plný text ve formátu HTML

Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study

Autor: Victor S. Blanchette, Bryce A. Kerlin, Rolf Ljung, Nikki Church, Valentina Uscatescu, Sonata Saulytė Trakymienė, L. Rusen, Despina Tseneklidou-Stoeter, Horst Beckmann, Gili Kenet

Publikováno v: Thrombosis research, Kidlington : Pergamon-Elsevier Science Ltd., 2020, vol. 189, p. 96-101

Introduction BAY 81-8973 (Kovaltry®), a recombinant factor VIII (rFVIII) product, was efficacious and well tolerated in paediatric previously treated patients (PTPs) with severe haemophilia A for ≥50 exposure days (EDs) in the LEOPOLD Kids study.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a711d7b9d4e4a7a7b1571ce30b248c3e
https://pubmed.ncbi.nlm.nih.gov/32197139

Zobrazit plný text záznamu

Prophylaxis vs. on‐demand treatment with BAY 81‐8973, a full‐length plasma protein‐free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)

Publikováno v: Journal of Thrombosis and Haemostasis

WOS: 000350548500005
PubMed ID: 25546368
BackgroundBAY 81-8973 is a new full-length human recombinant factor VIII product manufactured with technologies to improve consistency in glycosylation and expression to optimize clinical performance

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a4eb2c95999e1df608a170f7d836b5c
https://doi.org/10.1111/jth.12828

Zobrazit plný text záznamu

Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq

Autor: Y, Dargaud, C, Negrier, L, Rusen, J, Windyga, P, Georgiev, J, Bichler, C, Solomon, S, Knaub, T, Lissitchkov, R, Klamroth

Publikováno v: Haemophilia : the official journal of the World Federation of Hemophilia. 24(4)

For individuals with haemophilia A, prophylaxis with factor VIII (FVIII) is typically directed towards trough activity1 IU/dL; however, some patients still experience spontaneous bleeding events (sBEs).Aims were to evaluate relationships of endogenou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c71d645ccdbcef78d12437e772665e07
https://pubmed.ncbi.nlm.nih.gov/29855112

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání